Natália Polidorio, MD, PhD, on the Impact of Race on Therapeutic Outcomes in Triple-Negative Breast Cancer

Posted: Friday, April 5, 2024

Natália Polidorio, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses study findings that may potentially affect treatment decision-making for patients with early-stage triple-negative breast cancer, depending on their race and possibly other factors, as well as whether they receive neoadjuvant chemoimmunotherapy or chemotherapy alone.

---